KR101320261B1 - Ｗｉｓｐ 활성의 조절 및 검출을 위한 방법 및 조성물 - Google Patents

Ｗｉｓｐ 활성의 조절 및 검출을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101320261B1
KR101320261B1 KR1020077023542A KR20077023542A KR101320261B1 KR 101320261 B1 KR101320261 B1 KR 101320261B1 KR 1020077023542 A KR1020077023542 A KR 1020077023542A KR 20077023542 A KR20077023542 A KR 20077023542A KR 101320261 B1 KR101320261 B1 KR 101320261B1
Authority
KR
South Korea
Prior art keywords
wisp
cells
polypeptide
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077023542A
Other languages
English (en)
Korean (ko)
Other versions
KR20080003344A (ko
Inventor
루크 데스노이어스
엘렌 필바로프
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20080003344A publication Critical patent/KR20080003344A/ko
Application granted granted Critical
Publication of KR101320261B1 publication Critical patent/KR101320261B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020077023542A 2005-04-14 2006-04-13 Ｗｉｓｐ 활성의 조절 및 검출을 위한 방법 및 조성물 Expired - Fee Related KR101320261B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
US11/105,876 2005-04-14
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (2)

Publication Number Publication Date
KR20080003344A KR20080003344A (ko) 2008-01-07
KR101320261B1 true KR101320261B1 (ko) 2013-10-22

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077023542A Expired - Fee Related KR101320261B1 (ko) 2005-04-14 2006-04-13 Ｗｉｓｐ 활성의 조절 및 검출을 위한 방법 및 조성물

Country Status (16)

Country Link
US (2) US7455834B2 (enExample)
EP (1) EP1869086B1 (enExample)
JP (1) JP4979684B2 (enExample)
KR (1) KR101320261B1 (enExample)
CN (1) CN101198623B (enExample)
AU (1) AU2006236649B2 (enExample)
BR (1) BRPI0612184A8 (enExample)
CA (1) CA2604933C (enExample)
ES (1) ES2388993T3 (enExample)
IL (1) IL186095A (enExample)
MX (1) MX2007012798A (enExample)
NO (1) NO20075825L (enExample)
NZ (1) NZ561709A (enExample)
RU (1) RU2412201C2 (enExample)
WO (1) WO2006113402A1 (enExample)
ZA (1) ZA200708738B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
US20160279269A1 (en) * 2013-03-27 2016-09-29 Ge Healthcare As Method and reagent for preparing a diagnostic composition
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
CN112118857A (zh) * 2018-05-17 2020-12-22 株式会社橄榄生物科技 用于预防或治疗视网膜疾病的包含ccn5作为活性成分的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2001053486A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2004003158A2 (en) 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
WO2005025603A2 (en) 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2001053486A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2004003158A2 (en) 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Also Published As

Publication number Publication date
CN101198623B (zh) 2013-06-12
AU2006236649A2 (en) 2008-07-24
KR20080003344A (ko) 2008-01-07
NZ561709A (en) 2009-12-24
JP2008537958A (ja) 2008-10-02
AU2006236649A1 (en) 2006-10-26
RU2412201C2 (ru) 2011-02-20
CA2604933A1 (en) 2006-10-26
AU2006236649B2 (en) 2012-03-29
US7732567B2 (en) 2010-06-08
WO2006113402A1 (en) 2006-10-26
MX2007012798A (es) 2007-11-20
HK1112470A1 (en) 2008-09-05
EP1869086A1 (en) 2007-12-26
CN101198623A (zh) 2008-06-11
US20060147453A1 (en) 2006-07-06
US7455834B2 (en) 2008-11-25
ES2388993T3 (es) 2012-10-22
RU2007142005A (ru) 2009-05-20
IL186095A0 (en) 2008-01-20
BRPI0612184A8 (pt) 2017-12-26
JP4979684B2 (ja) 2012-07-18
EP1869086B1 (en) 2012-07-18
IL186095A (en) 2012-10-31
CA2604933C (en) 2014-07-08
ZA200708738B (en) 2009-01-28
NO20075825L (no) 2008-01-11
BRPI0612184A2 (pt) 2011-12-20
US20090148448A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
JP5611047B2 (ja) アクチビンレセプター様キナーゼ−１アンタゴニスト組成物とその使用方法
JP2007515949A (ja) スクリーニングアッセイ及び腫瘍治療の方法
JP2013256535A (ja) 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
JP4636497B2 (ja) Ｗｉｓｐ活性を調節し検出するための方法及び組成物
JP2007505131A (ja) Ｗｉｓｐアンタゴニストの使用方法
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
US20110159588A1 (en) Methods for Modulating a PDGF-AA Mediated Biological Response
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity
JP4166254B2 (ja) ボールカインポリペプチド及び核酸

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181015